NCT06184698View on ClinicalTrials.gov

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

March 1, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

liposomal irinotecan

liposomal irinotecan 70 mg/m²

DRUG

5-FU

5-FU 2400 mg/m²

DRUG

LV

5-FU 2400 mg/m²

DRUG

Bevacizumab

bevacizumab 5 mg/kg

Trial Locations (1)

050000

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER